The U.S. Food and Drug Administration (FDA) issued an emergency use authorization for an experimental new drug 
called peramivir, made by Biocryst Pharmaceuticals Inc and licensed to Shionogi & Co Ltd as Reuter stated. And this is a guideline about the use of Peramivir IV under Emergency Use Authorization for Health Care Providers in treating 2009 H1N1 Influenza.
The article provides brief explanation regarding the use of this neuroaminidase inhibitor which is shown a highly potent of activity against influenza A and B viruses as well activity against pandemic H1N1 swine flu origin viral strains. But, there are number of limitations to the safety and efficacy data available at this stage of Peramivir’s development as this peramivir is still being evaluated in phase 3 clinical trials.
You will be taken into sections explain : Peramivir IV Authorized Use, Dosage and Administration, Preparing Peramivir Injection, Dosage Forms and Strength, Contraindications, Warning and Precautions, Overal Safety of Peramivir, Recommendations for patient monitoring, The Use in Specific Conditions (pregnancy, Nursing mothers, pediatric, geriatric), how supplied/storage and handling and etc.
See Peramivir IV Guidelines for Healthcare Provider here in Peramivir IV article of pdf filetype (source: cdc.gov)
